Sorry, you need to enable JavaScript to visit this website.

VELTASSA authorized wholesale distributors and specialty pharmacies for the United States

Entities authorized by Vifor Pharma, Inc., to direct-purchase and resell VELTASSA*:

AmerisourceBergen Corporation

1-844-222-2273 1-800-252-8090 (IL) 1-800-422-7637 (CA) 1-800-552-2526 (NY) asd.customerservice@asdhealthcare.com

Cardinal Health

1-800-926-3161 orderexpress@cardinalhealth.com

McKesson Corporation

1-800-793-9875 plasma@mckesson.com

Morris & Dickson Co., LLC

1-800-338-3833

NETWORK OF AUTHORIZED SPECIALTY PHARMACIES WITHIN THE UNITED STATES AND UNITED STATES TERRITORIES

Specialty pharmacies in the VELTASSA network authorized to direct-purchase and dispense VELTASSA†:

  • Accredo Specialty Pharmacy
  • ACS Specialty Pharmacy
  • Noble Specialty Pharmacy
  • Walgreens Specialty Pharmacy

*We strive to provide the most accurate listing, but it may be subject to change.

†Non-network specialty pharmacies may purchase the product from the authorized distributors listed above and dispense to patients.

To obtain more information on the prescribing and dispensing of VELTASSA, please contact VELTASSA KONNECT at 1‑844‑870‑7597.

SEE MORE

INDICATION

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

top

INDICATION & Important Safety Information

Important Safety Information

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

CONTRAINDICATIONS

VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

INDICATION

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

WARNINGS AND PRECAUTIONS

Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnecemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnecemia. In clinical studies, hypomagnecemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnecemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnecemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.